Here is the latest stock price and chart of ISHITA DRUGS. For more details, see the ISHITA DRUGS company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Live BSE Quotes | Feb 1, 2023 02:01:00 PM | ||
---|---|---|---|
Price (Rs)53.80 | Open (Rs) 52.55 | High (Rs) 53.80 | Low (Rs) 51.30 |
% Change2.38 | Volume 1,102 | Value (Rs) 59,288 | 52-Week H/L 79.55 / 36.10 |
Live NSE Quotes |
---|
Not listed |
Change | |||||
---|---|---|---|---|---|
1 Day 2.38% | 1 Month 4.36% | 3 Months -12.59% | 1 Year 5.70% | 5 Years (CAGR)* 19.80% | 10 Years (CAGR)* 14.60% |
* Compound Annual Growth Rate
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* 2.72 | P/E Ratio (x) 19.79 | Market Cap (Rs m) 160.88 | P/BV (x) 1.77 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
![]() |
||
S&P BSE SENSEX ![]() |
||||||
PERIOD |
ISHITA DRUGS last traded price was up 2.4% to Rs 53.8 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.6%. And the benchmark S&P BSE SENSEX was at 59,736.2 (up 0.3%).
Over the last 30 days, the ISHITA DRUGS share price is up 4.0%. And over the last one year, ISHITA DRUGS share price is up 5.5%.
The current market capitalisation of ISHITA DRUGS stands at Rs 160.88 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of December 2022, company promoters held 49.32% stake in ISHITA DRUGS, with no shares having been pledged. To know more, check out the latest shareholding pattern of ISHITA DRUGS.
What else is happening in the markets today? Dig in...
The last traded price of ISHITA DRUGS was Rs 53.8 on the BSE, up 2.4% over the previous close.
The current market capitalisation of ISHITA DRUGS stands at Rs 161 m.
ISHITA DRUGS had an EPS of Rs 2.7 in the latest financial year.
Asian share markets advanced today following a rally overnight in US shares on signs of cooling inflation. This encouraged risk appetite ahead of the Federal Reserve's meeting.